DSCO begins Phase III Surfaxin trial

Discovery Laboratories (DSCO) began patient enrollment in a U.S. and European Phase III trial of Surfaxin to treat idiopathic respiratory distress syndrome (IRDS) in premature infants. The 500-patient...